The stock may react negatively to the continued revenue decline and weak guidance, despite the improved net loss. The one-time tax benefit masks underlying operational weakness. Traders should watch for further signs of deterioration in the core business and whether the company can achieve profitability with its reduced scale.
Price Chart
Executive Summary
Standard BioTools reported FY2025 revenue of $85.3 million, down 6% YoY, with Q4 revenue of $23.8 million, down 4% YoY. While net loss improved to $58.8 million (from $90.9 million) due to a one-time $38.4 million tax benefit, core operating performance declined. The company expects FY2026 revenue of $80-$85 million, signaling continued contraction. Despite $550 million in cash from the SomaLogic sale, the fundamental business is weakening.
Key Financial Metrics
Key Facts
- FY2025 revenue was $85.3 million, down 6% YoY; Q4 revenue was $23.8 million, down 4% YoY
- FY2025 net loss improved to $58.8 million from $90.9 million in 2024, but this was primarily due to a one-time $38.4 million tax benefit, not operational improvement
- Adjusted EBITDA loss was $62.6 million in 2025, only a 3% improvement from $64.2 million in 2024
- The company guided FY2026 revenue to $80-$85 million, indicating an expectation of continued revenue decline
- Consumables revenue fell 11% YoY in 2025, while instruments grew only 2% YoY, indicating weak core demand
- The company has $550 million in cash from the SomaLogic sale but is not profitable and expects revenue to decline further
Financial Impact
Revenue declined 6% YoY to $85.3 million, with a net loss of $58.8 million. FY2026 revenue is expected to decline further to $80-$85 million.
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Instruments | $25.4M | +2.0% |
| Consumables | $36.2M | -11.0% |
| Services | $23.7M | -7.0% |
Risk Factors
- Continued revenue decline in core business
- Failure to achieve profitability despite cost-cutting
- Dilution risk from potential M&A activity using the cash balance
- Weak guidance suggests further contraction in 2026
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-067026 |
| Document: lab-20260224.htm | 0001193125-26-067026 |
| Document: 0001193125-26-067026-index-headers.html | 0001193125-26-067026 |
| Document: 0001193125-26-067026-index.html | 0001193125-26-067026 |
| Document: 0001193125-26-067026.txt | 0001193125-26-067026 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 29, 2026 9w ago | 425 | $0.8739 $0.6518 | ▼ −25.41% | ▼ −30.43% | $0.7300 (−16.47%) |
Jul 28, 2026 9w ago | Press Release | $0.7947 $0.6500 | ▼ −18.21% | ▼ −21.59% | $0.7300 (−8.14%) |
Jul 20, 2026 10w ago | 425 | $0.8500 $0.6845 | ▼ −19.47% | ▼ −23.59% | $0.7300 (−14.12%) |
Jul 20, 2026 10w ago | S-4 | $0.8500 $0.6845 | ▼ −19.47% | ▼ −23.59% | $0.7300 (−14.12%) |
Jun 8, 2026 16w ago | 425 | $0.8032 $0.8873 | ▲ +10.47% | ▲ +8.84% | $0.7300 (−9.11%) |
Jun 8, 2026 16w ago | 8-K | $0.8032 $0.8873 | ▲ +10.47% | ▲ +8.84% | $0.7300 (−9.11%) |
Jun 8, 2026 16w ago | Press Release | $0.8032 $0.8873 | ▲ +10.47% | ▲ +8.84% | $0.7300 (−9.11%) |
Apr 24, 2026 23w ago | 8-K | $0.9000 $1.09 | ▼ −21.11% | ▼ −16.15% | $0.7300 (+18.89%) |
Apr 21, 2026 23w ago | Press Release | $0.9600 $0.9900 | ▲ +3.13% | ▼ −1.79% | $0.7300 (−23.96%) |
Feb 24, 2026 31w ago | 8-K | $1.17 $0.9600 | ▲ +17.95% | ▲ +12.71% | $0.7300 (+37.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access